Analysts forecast that Sunesis Pharmaceuticals (NASDAQ:SNSS) will announce earnings per share of ($0.29) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Sunesis Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.31) and the highest estimate coming in at ($0.27). Sunesis Pharmaceuticals posted earnings per share of ($0.47) in the same quarter last year, which would indicate a positive year over year growth rate of 38.3%. The firm is scheduled to issue its next quarterly earnings results on Monday, May 14th.
According to Zacks, analysts expect that Sunesis Pharmaceuticals will report full-year earnings of ($1.04) per share for the current financial year, with EPS estimates ranging from ($1.09) to ($0.94). For the next financial year, analysts expect that the company will report earnings of ($1.16) per share, with EPS estimates ranging from ($1.16) to ($1.15). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that follow Sunesis Pharmaceuticals.
Sunesis Pharmaceuticals (NASDAQ:SNSS) last announced its quarterly earnings data on Thursday, March 8th. The biopharmaceutical company reported ($0.21) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.29) by $0.08.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Geode Capital Management LLC boosted its holdings in shares of Sunesis Pharmaceuticals by 105.2% during the 4th quarter. Geode Capital Management LLC now owns 125,489 shares of the biopharmaceutical company’s stock valued at $463,000 after acquiring an additional 64,343 shares during the last quarter. Vatera Holdings LLC purchased a new stake in shares of Sunesis Pharmaceuticals during the 4th quarter valued at about $673,000. BlackRock Inc. boosted its holdings in shares of Sunesis Pharmaceuticals by 9.5% during the 4th quarter. BlackRock Inc. now owns 130,573 shares of the biopharmaceutical company’s stock valued at $482,000 after acquiring an additional 11,351 shares during the last quarter. Wells Fargo & Company MN boosted its holdings in shares of Sunesis Pharmaceuticals by 127.6% during the 3rd quarter. Wells Fargo & Company MN now owns 95,247 shares of the biopharmaceutical company’s stock valued at $185,000 after acquiring an additional 53,396 shares during the last quarter. Finally, Vanguard Group Inc. boosted its holdings in shares of Sunesis Pharmaceuticals by 4.1% during the 2nd quarter. Vanguard Group Inc. now owns 605,759 shares of the biopharmaceutical company’s stock valued at $1,635,000 after acquiring an additional 23,819 shares during the last quarter. 53.04% of the stock is currently owned by hedge funds and other institutional investors.
SNSS stock traded up $0.07 during trading on Friday, hitting $2.68. 40,379 shares of the stock traded hands, compared to its average volume of 292,554. Sunesis Pharmaceuticals has a 1 year low of $1.82 and a 1 year high of $7.69. The company has a market capitalization of $89.31, a price-to-earnings ratio of -1.85 and a beta of 1.81.
ILLEGAL ACTIVITY NOTICE: “Sunesis Pharmaceuticals (SNSS) Expected to Post Earnings of -$0.29 Per Share” was originally reported by Week Herald and is the property of of Week Herald. If you are reading this article on another website, it was copied illegally and republished in violation of U.S. and international copyright legislation. The original version of this article can be accessed at https://weekherald.com/2018/04/18/sunesis-pharmaceuticals-snss-expected-to-post-earnings-of-0-29-per-share.html.
Sunesis Pharmaceuticals Company Profile
Sunesis Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The company is developing vosaroxin, an anticancer quinolone derivative for the treatment of acute myeloid leukemia (AML).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sunesis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.